Literature DB >> 16225931

Poor premorbid school performance is associated with later cigarette smoking among schizophrenia patients.

Kaisa Riala1, Helinä Hakko, Matti Isohanni, Jari Jokelainen, Mark Weiser, Pirkko Räsänen.   

Abstract

Schizophrenia patients who smoke have been postulated to have genetically mediated dysfunctional nicotinic neurotransmission. We hypothesized that this nicotinic dysfunction would manifest as poorer school performance in adolescence, before the onset of illness, in smoking compared with non-smoking schizophrenia patients. Over a 31-year follow-up period, 100 (65 men) cohort members of the Northern Finland 1966 Birth Cohort were hospitalized and diagnosed with DSM-III-R schizophrenia. The information on school performance was obtained at the end of compulsory schooling at age 16 years. The information on smoking habits was gathered from a questionnaire mailed to cohort members at the age of 31 years. Compared with non-smoking schizophrenia patients, schizophrenia patients who smoked in adulthood had lower overall mean grades, lower mean grades in combined mathematical subjects, and lower grades in music. Poor school performance might represent premorbid nicotinergic dysfunction associated with cognitive deficits in future smokers among schizophrenia patients compared with those who remained non-smokers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225931     DOI: 10.1016/j.psychres.2005.07.014

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

Review 1.  Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review.

Authors:  Erika Jääskeläinen; Marianne Haapea; Nina Rautio; Pauliina Juola; Matti Penttilä; Tanja Nordström; Ina Rissanen; Anja Husa; Emmi Keskinen; Riikka Marttila; Svetlana Filatova; Tiina-Mari Paaso; Jenni Koivukangas; Kristiina Moilanen; Matti Isohanni; Jouko Miettunen
Journal:  Schizophr Res Treatment       Date:  2015-05-18

2.  Association between lower estimated premorbid intelligence quotient and smoking behavior in patients with schizophrenia.

Authors:  Shinsuke Hidese; Junko Matsuo; Ikki Ishida; Moeko Hiraishi; Toshiya Teraishi; Miho Ota; Kotaro Hattori; Hiroshi Kunugi
Journal:  Schizophr Res Cogn       Date:  2018-10-09

3.  mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia.

Authors:  Cláudia Régio Brambilla; Tanja Veselinović; Ravichandran Rajkumar; Jörg Mauler; Linda Orth; Andrej Ruch; Shukti Ramkiran; Karsten Heekeren; Wolfram Kawohl; Christine Wyss; Elena Rota Kops; Jürgen Scheins; Lutz Tellmann; Frank Boers; Bernd Neumaier; Johannes Ermert; Hans Herzog; Karl-Josef Langen; N Jon Shah; Christoph Lerche; Irene Neuner
Journal:  Hum Brain Mapp       Date:  2020-03-09       Impact factor: 5.038

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.